People: CASI Pharmaceuticals Inc (CASI.OQ)
Dr. Ken Keyong Ren, Ph.D., is Director of the Company. Dr. Ren joined the Company in April 2012 as interim CEO and was appointed CEO in April 2013. Dr. Ren served as CEO until April 2, 2019. Dr. Ren has been a director of the Company since December 2014. Prior to joining the Company, from 2005-2012, Dr. Ren was the president of Accelovance (China), a subsidiary of Accelovance, Inc., which is a Maryland-based contract research organization. Prior to Accelovance, Dr. Ren was the founder of New Jersey-based AHT Inc., which merged with Novemed, a portfolio investment of a blue-chip public company in Hong Kong. He was a co-founder of the China Innovation Center for Life Science (U.S.A.) Corp., a New York-based consulting firm in partnership with the Chinese Ministry of Science and Technology which provided consulting services to health-care and pharmaceutical companies in both the U.S. and China. Over the past 15 years, Dr. Ren has been involved in several U.S./China based start-up companies in pharmaceutical development or services. Dr. Ren was a research scientist at Pfizer from 1993–1995 and a Research Fellow at Rockefeller University from 1990–1993. He received his medical degree at the Shandong University School of Medicine in China in 1986 and a Ph.D. from State University of New York at Buffalo in 1990. Dr. Ren’s qualifications to serve on the Board of Directors include his extensive leadership experience and background in the healthcare and pharmaceutical industries, which make him well qualified to serve on our Board of Directors.
|Total Annual Compensation, USD||547,980|
|Restricted Stock Award, USD||--|
|Long-Term Incentive Plans, USD||--|
|All Other, USD||689,169|
|Fiscal Year Total, USD||1,237,150|